BCR and lymphoma: Gain-of-function CD79 and MyD88 mutations hyperactivate BCR/TLR9 signaling in several types of lymphoma, including the diffuse large B cell lymphoma (DLBCL) MyD88/CD79B-mutated (MCD) subtype (18–20).